These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

171 related articles for article (PubMed ID: 17449210)

  • 21. Population pharmacokinetics of levofloxacin, gatifloxacin, and moxifloxacin in adults with pulmonary tuberculosis.
    Peloquin CA; Hadad DJ; Molino LP; Palaci M; Boom WH; Dietze R; Johnson JL
    Antimicrob Agents Chemother; 2008 Mar; 52(3):852-7. PubMed ID: 18070980
    [TBL] [Abstract][Full Text] [Related]  

  • 22. Susceptibility to moxifloxacin of pneumococci isolated in English hospitals participating in the European Antimicrobial Resistance Surveillance System (EARSS) in 2003.
    Johnson AP; Lamagni TL; Wale M; Cavendish S; Bishop L; Alhaddad N; Warner M; Livermore DM; Duckworth G; George RC
    Int J Antimicrob Agents; 2005 Jun; 25(6):539-41. PubMed ID: 15890501
    [TBL] [Abstract][Full Text] [Related]  

  • 23. Frequency of 1st- and 2nd-step topoisomerase mutations in Streptococcus pneumoniae following levofloxacin and moxifloxacin exposure.
    Hovde LB; Simonson DA; Rotschafer JC
    Diagn Microbiol Infect Dis; 2008 Mar; 60(3):295-9. PubMed ID: 18053674
    [TBL] [Abstract][Full Text] [Related]  

  • 24. Serum bactericidal activity of levofloxacin against Streptococcus pneumoniae.
    Shah PM
    J Antimicrob Chemother; 1999 Jun; 43 Suppl C():61-5. PubMed ID: 10404340
    [TBL] [Abstract][Full Text] [Related]  

  • 25. Pharmacodynamics of moxifloxacin and levofloxacin at simulated epithelial lining fluid drug concentrations against Streptococcus pneumoniae.
    Florea NR; Tessier PR; Zhang C; Nightingale CH; Nicolau DP
    Antimicrob Agents Chemother; 2004 Apr; 48(4):1215-21. PubMed ID: 15047522
    [TBL] [Abstract][Full Text] [Related]  

  • 26. Designing fluoroquinolone breakpoints for Streptococcus pneumoniae by using genetics instead of pharmacokinetics-pharmacodynamics.
    Smith HJ; Noreddin AM; Siemens CG; Schurek KN; Greisman J; Hoban CJ; Hoban DJ; Zhanel GG
    Antimicrob Agents Chemother; 2004 Sep; 48(9):3630-5. PubMed ID: 15328145
    [TBL] [Abstract][Full Text] [Related]  

  • 27. Pharmacodynamic activity of ertapenem versus penicillin-susceptible and penicillin-non-susceptible Streptococcus pneumoniae using an in vitro model.
    Zhanel GG; Derkatch S; Laing N; Noreddin AM; Hoban DJ
    J Antimicrob Chemother; 2007 Jan; 59(1):144-7. PubMed ID: 17079238
    [TBL] [Abstract][Full Text] [Related]  

  • 28. Comparison of the bactericidal activity of moxifloxacin and levofloxacin against Staphylococcus aureus, Staphylococcus epidermidis, Escherichia coli and Klebsiella pneumoniae.
    Lemmen SW; Häfner H; Klik S; Lütticken R; Zolldann D
    Chemotherapy; 2003 May; 49(1-2):33-5. PubMed ID: 12714807
    [TBL] [Abstract][Full Text] [Related]  

  • 29. Comparative in vitro activity of penicillin G, levofloxacin, moxifloxacin, telithromycin, pristinamycin, quinupristin-dalfopristin and linezolid against ofloxacin-intermediate and -resistant Streptococcus pneumoniae.
    Frédénucci I; Chomarat M; Bercion R; Carricajo A; Celard M; Croizé J; Delubac F; Fèvre D; Fuhrmann C; Helfre M; Letouzey MN; Lelièvre H; Mandjee A; Marthelet P; Meley R; Perrier-Gros-Claude JD; Ros A; Roure C; Smati S; Thierry J; Tous J
    Clin Microbiol Infect; 2002 Oct; 8(10):680-3. PubMed ID: 12390289
    [TBL] [Abstract][Full Text] [Related]  

  • 30. Ceftriaxone acts synergistically with levofloxacin in experimental meningitis and reduces levofloxacin-induced resistance in penicillin-resistant pneumococci.
    Flatz L; Cottagnoud M; Kühn F; Entenza J; Stucki A; Cottagnoud P
    J Antimicrob Chemother; 2004 Feb; 53(2):305-10. PubMed ID: 14729741
    [TBL] [Abstract][Full Text] [Related]  

  • 31. Urinary bactericidal activity of single doses (250, 500, 750 and 1000 mg) of levofloxacin against fluoroquinolone-resistant strains of Escherichia coli.
    Stein GE; Schooley SL; Nicolau DP
    Int J Antimicrob Agents; 2008 Oct; 32(4):320-5. PubMed ID: 18715762
    [TBL] [Abstract][Full Text] [Related]  

  • 32. parE mutations in Streptococcus pneumoniae may reduce bactericidal activity of respiratory fluoroquinolones.
    Sun HK; Du X; DeRyke CA; Doern GV; Nicolau DP
    Int J Antimicrob Agents; 2007 Feb; 29(2):230-2. PubMed ID: 17204405
    [No Abstract]   [Full Text] [Related]  

  • 33. Penicillin-resistant streptococcus pneumoniae: review of moxifloxacin activity.
    Dalhoff A; Krasemann C; Wegener S; Tillotson G
    Clin Infect Dis; 2001 Mar; 32 Suppl 1():S22-9. PubMed ID: 11249825
    [TBL] [Abstract][Full Text] [Related]  

  • 34. Activity of oral agents against pediatric isolates of Streptococcus pneumoniae.
    Black J; Moland ES; Chartrand SA; Thomson KS
    Diagn Microbiol Infect Dis; 2001 Mar; 39(3):195-7. PubMed ID: 11337189
    [TBL] [Abstract][Full Text] [Related]  

  • 35. Factors compromising the activity of moxifloxacin against intracellular Staphylococcus aureus.
    Nguyen HA; Grellet J; Dubois V; Saux MC; Quentin C
    J Antimicrob Chemother; 2007 Apr; 59(4):755-8. PubMed ID: 17353222
    [TBL] [Abstract][Full Text] [Related]  

  • 36. In vitro activity of moxifloxacin against community respiratory pathogens in Qatar.
    Elshafie SS; Al-Kuwari J
    Int J Antimicrob Agents; 2004 Sep; 24(3):309-10. PubMed ID: 15325441
    [No Abstract]   [Full Text] [Related]  

  • 37. Maternal and fetal blood levels of moxifloxacin, levofloxacin, cefepime and cefoperazone.
    Ozyuncu O; Nemutlu E; Katlan D; Kir S; Beksac MS
    Int J Antimicrob Agents; 2010 Aug; 36(2):175-8. PubMed ID: 20418070
    [TBL] [Abstract][Full Text] [Related]  

  • 38. A randomized trial comparing the cardiac rhythm safety of moxifloxacin vs levofloxacin in elderly patients hospitalized with community-acquired pneumonia.
    Morganroth J; Dimarco JP; Anzueto A; Niederman MS; Choudhri S;
    Chest; 2005 Nov; 128(5):3398-406. PubMed ID: 16304291
    [TBL] [Abstract][Full Text] [Related]  

  • 39. Consumption patterns and in vitro resistance of Streptococcus pneumoniae to fluoroquinolones.
    Simoens S; Verhaegen J; van Bleyenbergh P; Peetermans WE; Decramer M
    Antimicrob Agents Chemother; 2011 Jun; 55(6):3051-3. PubMed ID: 21464243
    [TBL] [Abstract][Full Text] [Related]  

  • 40. Comparative study of the mutant prevention concentrations of moxifloxacin, levofloxacin, and gemifloxacin against pneumococci.
    Credito K; Kosowska-Shick K; McGhee P; Pankuch GA; Appelbaum PC
    Antimicrob Agents Chemother; 2010 Feb; 54(2):673-7. PubMed ID: 20008781
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 9.